Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Lung Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
80 drugs · 288 active trials
21 drugs · 605 active trials
51 drugs · 1,369 active trials
Outside the funnel: Phase not stated 2 · Withdrawn 2. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 19 minutes agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Carboplatin | Phase 4 | Phase 4 | 241 | 118 | 220 | 822 | 0 | — | — | 1994-12 |
| Cisplatin | Phase 4 | Phase 4 | 143 | 58 | 173 | 556 | 0 | — | — | 1993-01 |
| Nab-paclitaxel | Phase 4 | Phase 4 | 46 | 22 | 21 | 110 | 0 | — | — | 2003-09 |
| Tislelizumab | Phase 4 | Phase 4 | 46 | 20 | 25 | 78 | 0 | — | — | Nov 30, 2017 |
| Chemotherapy | Phase 4 | Phase 4 | 35 | 24 | 19 | 101 | 0 | — | — | 1997-01 |
| Firmonertinib | Phase 4 | Phase 4 | 31 | 20 | 5 | 44 | 0 | — | — | Dec 30, 2016 |
| Crizotinib | Phase 4 | Phase 4 | 15 | 4 | 16 | 44 | 0 | — | — | 2009-09 |
| Irinotecan | Phase 4 | Phase 4 | 9 | 6 | 6 | 78 | 0 | — | — | 1997-04 |
| Ensartinib | Phase 4 | Phase 4 | 9 | 2 | 2 | 15 | 0 | — | — | May 10, 2017 |
| Dexamethasone | Phase 4 | Phase 4 | 8 | 4 | 12 | 36 | 0 | — | — | 2004-08 |
| Carboplatin OR Cisplatin | Phase 4 | Phase 4 | 7 | 4 | 2 | 9 | 0 | — | — | Aug 27, 2019 |
| Immune Checkpoint Inhibitor | Phase 4 | Phase 4 | 4 | 4 | 1 | 5 | 0 | — | — | Oct 26, 2017 |
| Icotinib | Phase 4 | Phase 4 | 3 | 1 | 10 | 44 | 0 | — | — | 2009-02 |
| Tucatinib | Phase 4 | Phase 4 | 3 | 0 | 0 | 3 | 0 | — | — | Jan 11, 2021 |
| Sunitinib | Phase 4 | Phase 4 | 2 | 1 | 2 | 24 | 0 | — | — | 2004-07 |
| Pegfilgrastim | Phase 4 | Phase 4 | 2 | 1 | 1 | 14 | 0 | — | — | 2002-06 |
| Taxol | Phase 4 | Phase 4 | 1 | 1 | 0 | 8 | 0 | — | — | 1999-08 |
| Zoledronic Acid | Phase 4 | Phase 4 | 0 | 0 | 5 | 12 | 0 | — | — | 1998-08 |
| Thalidomide | Phase 4 | Phase 4 | 0 | 0 | 2 | 11 | 0 | — | — | 2000-01 |
| Vinblastine | Phase 4 | Phase 4 | 0 | 0 | 6 | 10 | 0 | — | — | 1994-07 |
| Ibandronic Acid | Phase 4 | Phase 4 | 0 | 0 | 0 | 1 | 0 | — | — | 2007-07 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.